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Abstract: Voclosporin, a novel immunomodulatory drug inhibiting the calcineurin enzyme, 
was developed to prevent organ graft rejection and to treat autoimmune diseases. The chemical 
structure of voclosporin is similar to that of cyclosporine A, with a difference in one amino 
acid, leading to superior calcineurin inhibition and less variability in plasma concentration. 
Compared with placebo, voclosporin may significantly reduce inflammation and prevent recur-
rences of inflammation in patients with noninfectious uveitis. Future studies have to show if 
these advantages are accompanied by greater clinical efficacy and fewer side effects compared 
with the classic calcineurin inhibitors.
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Introduction
Noninfectious uveitis is often chronic and relapsing, and typically affects people aged 
20–60 years, ie, the working population. Nevertheless, children and older people can 
also be affected, albeit less frequently, and may have different underlying diseases.1–3 
Visual impairment occurs in many patients with uveitis, but blindness is a relatively 
rare complication in recent decades due to more potent drugs and more aggressive 
treatment strategies. Worldwide, uveitis is one of the five most important reasons for 
visual loss and accounts for 10% of cases of blindness due to secondary complica-
tions, eg, macular edema.1,4,5
Patients with uveitis reported markedly reduced general and vision-related quality 
of life compared with normal subjects.6 The vision-related quality of life in patients 
with noninfectious uveitis is even worse compared with patients with infectious 
uveitis, and this is attributed to the often chronic relapsing course of the noninfec-
tious   disease.7 Furthermore, general quality of life in patients with uveitis on chronic 
systemic immunosuppressive treatment has been shown to be reduced, being related 
to visual acuity and disease duration.8 Therefore, treatment of uveitis with immuno-
modulatory agents has to be not only effective but also well tolerated by patients in 
terms of safety and quality of life.
Noninfectious uveitis may be limited to the eye itself (idiopathic uveitis) or be 
associated with a systemic autoimmune disease. The pathogenesis of noninfectious 
uveitis is thought to be due to a disruption of ocular immunotolerance. The blood 
retinal barrier and blood aqueous barrier are anatomical barriers that protect the eye 
from otherwise harmful immune reactions. Furthermore, the aqueous fluid and vitreous 
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intestinal polpeptide, alpha-melanocyte-stimulating hormone, 
and calcitonin-releasing protein) regulating the activity of 
leukocytes.9,10 If ocular immune privilege is broken, the uvea 
and adjacent tissue are infiltrated and damaged by inflamma-
tory cells. Bacterial and viral antigens may trigger immune 
reactions, as well as the body’s own antigens, mediated by 
trauma or inflammation.11,12 Uveitis is an autoimmune disease 
primarily mediated by CD4-positive T helper cells.13 These 
T cells produce a number of proinflammatory cytokines, such 
as interferon gamma and several types of interleukins. These 
cytokines spread inflammation to further immune cells.
Corticosteroids are usually the first-line treatment in 
autoimmune uveitis. Application (topical, periorbital, intra-
vitreal injection, oral formulations) and dosing depend on 
the anatomical type of uveitis according to the Standardiza-
tion of Uveitis Nomenclature classification and severity of 
inflammation.14 If inflammation is restricted to the anterior 
eye chamber, corticosteroid eyedrops are initiated. Systemic 
corticosteroids are administered for inflammation of the 
posterior eye segment including the vitreous. If inflammation 
is severe, the initial dosage is usually 1 mg/kg body weight, 
decreasing by 10 mg weekly. Low-dose corticosteroids at 
a dosage around 0.1 mg/kg body weight are often given as 
maintenance therapy to prevent further flares. Second-line 
immunosuppressive therapy is administered if inflammation 
requires high corticosteroid dosages over the long term or 
if low-dose treatment is accompanied by adverse effects. 
Antimetabolites (azathioprine, methotrexate) and T cell 
inhibitors (cyclosporine, mycophenolic acid) are the most 
commonly used corticosteroid-sparing drugs in noninfec-
tious uveitis. Azathioprine is a prodrug that is metabolized 
into 6-mercaptopurine, which acts as a purine synthesis 
inhibitor, inhibiting DNA synthesis and consequently 
proliferation of cells. Azathioprine is usually administered 
at a dosage of 2 mg/kg daily. Azathioprine is moderately 
effective as a single corticosteroid-sparing immunosuppres-
sive agent in terms of controlling inflammation and having 
corticosteroid-sparing benefits, but requires several months 
to achieve treatment goals.15 Methotrexate inhibits tetrahy-
drofolate synthesis by inhibiting the enzyme dihydrofolate 
reductase. Folic acid is important for the synthesis of DNA, 
RNA, and proteins. Methotrexate reduces B and T cell pro-
liferation, and is commonly used at a dosage of 15–25 mg 
weekly in adult patients with uveitis.   Methotrexate is also 
effective for intraocular lymphoma when given directly 
into the eye.16 Cyclosporine A binds to cyclophilin, thereby 
inhibiting   calcineurin. Calcineurin dephosphorylates the 
nuclear factor of activated T cells, which is responsible 
for the transcription of interleukin-2. Cyclosporine A thus 
leads to reduced functioning of T cells. Cyclosporine A at 
a dosage of 151–250 mg/day is modestly effective for con-
trolling intraocular inflammation.17 Mycophenolic acid 
inhibits inosine monophosphate dehydrogenase, which is 
important for purine synthesis. Mycophenolic acid reduces 
proliferation of B and T lymphocytes. At the preferred dos-
age of 720 mg twice daily, mycophenolic acid is effective 
and well   tolerated.18 A similar drug, mycophenolate mofetil, 
has proven to be effective in managing ocular inflammation 
in approximately half of patients treated.19
Nowadays, biologic agents, such as tumor necrosis factor 
alpha inhibitors (adalimumab, infliximab) have demonstrated 
good efficacy in otherwise treatment-refractory uveitis.20 
However, high treatment costs and the lack of randomized 
controlled trials limit their use to selected cases.
Chemical and pharmacologic data
Voclosporin (Lux Biosciences Inc, Jersey City, NJ) was devel-
oped by Isotechnika Pharma Inc, Edmonton, AB,   Canada, 
for the treatment of autoimmune diseases and prevention of 
allograft rejection. The molecular structure is very similar 
to that of cyclosporine A, with the exception of a functional 
group in an amino acid.21 The molecular structure is already 
shown elsewhere.22–24 Voclosporin is a calcineurin inhibitor 
leading to inhibition of activation of T cells and a decrease 
of proinflammatory cytokine (interleukin-2, interleukin-4, 
interferon gamma) production. Voclosporin consists of two 
isomers, ie, a trans and a cis isomer. These two isomers differ 
in the orientation of one modified functional group. While 
early clinical and nonclinical studies were performed using 
a virtually equal mixture of both isomers, ie, ISA247, nowa-
days the clinical studies use the more potent trans   isomer, 
ie, LX211.25,26 The blood concentrations of voclosporin may 
be quantified by mass spectrometry.27 ISA-247/LX-211 
  demonstrated good absorption after oral administration in 
rabbits, cats, and dogs. The half-life is 6.0–8.8 hours and 
systemic exposure is dose-related.32 Time to peak concen-
tration is 1.5–2.0 hours after oral administration. ISA-247/
LX-211 undergoes extensive first-pass metabolism, involving 
the cytochrome P450 enzyme. Fecal excretion is the primary 
route of elimination.24
ISA247 leads to comparable or even higher inhibition 
of lymphocyte proliferation, T cell activation, and cytokine 
production than that achieved by cyclosporine A in nonhuman 
primates. Allografts in monkeys treated with ISA247 sur-
vive longer than those treated with cyclosporine A.28,29 This 
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with cyclosporine A is also observed in vitro.30 Voclosporin 
(LX211) has achieved effective suppression of experimental 
uveitis in rats, and furthermore inhibition of human T cell 
proliferation and function in vitro.31
Clinical data
In a 12-week, randomized, double-blind, placebo-controlled 
Phase II study of 201 patients with plaque psoriasis, ISA247 
appeared safe and effective for treating moderate to severe 
psoriasis. The most effective concentration was 1.5 mg/kg/day, 
but serum creatinine increased in this patient group.33 The effi-
cacy of ISA247 in psoriasis was confirmed by a Phase III study 
of 451 patients for 24 weeks. The highest administered dose 
(0.4 mg/kg twice a day) achieved the best results for psoriasis 
area and severity index.34 Both psoriasis studies examined 
quality of life between placebo and verum groups and found 
the highest verum concentrations to improve disease-related 
quality of life.35,36 Further studies are evaluating the effect of 
voclosporin in kidney and renal transplantation and the safety 
and tolerability of the ophthalmic solution in patients with 
keratoconjunctivitis sicca.
Published data on side effects in patients treated with 
voclosporin for uveitis are limited (see Table 1). The mode 
of action of voclosporin is similar to that of cyclosporine 
A, with probably similar side effects. Data on development 
of malignancy while on treatment with cyclosporine A for 
inflammatory ocular disease are also scarce. Lane et al did 
not observe an increased risk of malignancy in patients with 
severe ocular inflammatory eye disease treated with systemic 
  immunosuppressive agents compared with patients treated 
with systemic corticosteroids.37 Kempen et al followed on 
with data showing that calcineurin inhibitors would prob-
ably not increase cancer risk to a degree that outweighs 
the expected benefits of therapy for ocular inflammation.38 
Voclosporin demonstrated less nephrotoxicity compared with 
calcineurin in animal studies.32
Uveitis trials
Up until now, three clinical studies of voclosporin in the 
treatment of noninfectious uveitis have been performed. 
The LUMINATE (Lux Uveitis Multicenter Investigation of a 
New Approach to Treatment) clinical development program 
was initiated in 2007 by Lux Biosciences Inc to assess the 
safety and efficacy of voclosporin for the treatment, main-
tenance, and control of all forms of noninfectious uveitis. 
The aim of the LUMINATE program, which was recently 
presented by Anglade et al, was to ensure that voclosporin 
would become the first corticosteroid-sparing agent to be 
approved by the US Food and Drug Administration for 
noninfectious uveitis. Three randomized, double-blind, 
placebo-controlled, Phase II/III trials in patients with nonin-
fectious, sight-threatening uveitis were performed. The first 
study included patients with active intermediate, anterior 
and intermediate, posterior, or   panuveitis. The second study 
included patients with quiescent intermediate, anterior and 
intermediate, posterior, or panuveitis in patients requiring 
systemic immunosuppression. The third study included 
patients with active anterior uveitis requiring systemic 
immunosuppression. The final results of the three studies 
are not yet comprehensively published, but some data are 
available.23,39,40 In patients with active intermediate, poste-
rior, and panuveitis, voclosporin 0.4 mg/kg and 0.6 mg/kg 
twice daily reduced inflammation by about 50% compared 
with 29% in the placebo group at 16 and 24 weeks. Uveitis 
recurrences were reduced by 50% in the group with quiescent 
uveitis. In all three studies, 96%–98% of patients were able 
to reduce their oral prednisolone dosage to #5 mg daily. 
However, no significant effect for voclosporin was observed 
for anterior uveitis.
Nearly 20% of patients treated with 0.6 mg twice daily 
experienced deterioration of renal function. This was seen in 
only 8.2% of patients in the 0.4 mg/kg group. Hypertension 
was experienced by 7.5% of patients in the 0.4 mg/kg group 
and by 10.3% of patients in the 0.6 mg/kg group.41
The recently presented data are very promising, but the 
Food and Drug Administration has requested an additional 
clinical trial prior to final approval of voclosporin for the 
Table 1 Safety data from clinical trials of voclosporin for plaque 
psoriasis
Bissonnette et al33 Most frequently reported adverse events:  
nausea, headache, abnormal chemistry changes
0.5 mg/kg/day group showed a similar percentage   
of side effects compared with placebo, and  
no change in mean serum creatinine levels
1.5 mg/kg/day group showed a significant  
increase in mean creatinine levels
Neither group had a significant increase  
in infection rate, mean blood pressure, serum  
lipid parameters, or significant electrocardiogram  
parameter alterations
Papp et al34 Most frequently reported adverse events:  
headache, nasopharyngitis, and upper respiratory  
tract infections
All three groups (0.4, 0.6, 0.8 mg/kg/day) showed  
no significant changes in renal function, blood  
pressure, or mean lipid concentrations  
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Dovepress 
Dovepress
1312
Roesel et al
treatment of noninfectious uveitis. Therefore, Lux   Biosciences 
Inc is currently planning a Phase III study to assess the 
efficacy and safety of voclosporin in patients with active 
noninfectious intermediate, posterior, or panuveitis. The 
mean change in vitreous haze from baseline to 12-week 
follow-up and time to treatment failure is the primary out-
come measure of this trial. Secondary outcome measures are 
mean daily systemic corticosteroid dose during weeks 12–24, 
time to augmentation with corticosteroid therapy, and mean 
change from baseline in the Vision Specific Role Difficulties 
subscale of the National Eye Institute Visional Functioning 
Questionnaire. If successful, voclosporin may become the first 
corticosteroid-sparing agent approved by the Food and Drug 
Administration for the treatment of noninfectious uveitis.
Conclusion
Voclosporin, a novel immunomodulatory drug inhibiting the 
calcineurin enzyme, may significantly reduce inflammation 
and prevent recurrences of inflammation in patients with 
noninfectious uveitis. If the additional Phase III study 
confirms its effectiveness, voclosporin may become the 
first immunosuppressive drug approved by the Food and 
Drug Administration for the treatment of noninfectious   
uveitis.
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